Please assess the completion status of the following clinical trial:

Trial Title: Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Both genders~* For women of childbearing age, they should use or be willing to use a double contraceptive method during the study. A urine pregnancy test to exclude pregnancy will be performed prior to study initiation.~* Written consent after information provided by the patient or the legal representative in the event that the patient cannot consent.~* Upper respiratory or lower respiratory tract infection, as in Annexes II and III respectively.~* Positive respiratory secretion test for SARS-CoV-2 virus by molecular techniques or positive blood IgM titers.~Exclusion Criteria:~* Under 18 years of age~* Denial of written consent~* Any patient case where it has been decided not to rejuvenate~* Serum AST values greater than 5 times the upper normal range~* QTc interval in rest electrocardiogram greater than 500msecs~* Pregnancy or lactation. Urgent pregnancy test to exclude pregnancy before inclusion in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- UNIKINON (Chloroquine phosphate) (Type: EXPERIMENTAL): Once a patient is considered eligible for the study, they will receive oral chloroquine phosphate. The total duration of treatment will be 7 days. The dosage will be 500mg every 12 hours. It is clarified that any other treatment at the discretion of the therapist is permitted except for the administration of hydroxychloroquine.

Based on this trial design, predict the completion outcome and termination type (if applicable).